DK2582721T3 - USEFUL ANTIBODIES FOR PASSIVE INFLUENZA IMMUNIZATION - Google Patents

USEFUL ANTIBODIES FOR PASSIVE INFLUENZA IMMUNIZATION Download PDF

Info

Publication number
DK2582721T3
DK2582721T3 DK11796555.8T DK11796555T DK2582721T3 DK 2582721 T3 DK2582721 T3 DK 2582721T3 DK 11796555 T DK11796555 T DK 11796555T DK 2582721 T3 DK2582721 T3 DK 2582721T3
Authority
DK
Denmark
Prior art keywords
ser
thr
gly
val
leu
Prior art date
Application number
DK11796555.8T
Other languages
Danish (da)
English (en)
Inventor
Lawrence M Kauvar
Stote Ellsworth
William Usinger
Krista Maureen Mccutcheon
Minha Park
Original Assignee
Trellis Bioscience Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trellis Bioscience Llc filed Critical Trellis Bioscience Llc
Application granted granted Critical
Publication of DK2582721T3 publication Critical patent/DK2582721T3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018Orthomyxoviridae, e.g. influenza virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Inorganic Chemistry (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK11796555.8T 2010-06-17 2011-06-17 USEFUL ANTIBODIES FOR PASSIVE INFLUENZA IMMUNIZATION DK2582721T3 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US35597810P 2010-06-17 2010-06-17
US201161443103P 2011-02-15 2011-02-15
US201161445455P 2011-02-22 2011-02-22
PCT/US2011/040982 WO2011160083A1 (en) 2010-06-17 2011-06-17 Antibodies useful in passive influenza immuization

Publications (1)

Publication Number Publication Date
DK2582721T3 true DK2582721T3 (en) 2018-10-01

Family

ID=45348575

Family Applications (1)

Application Number Title Priority Date Filing Date
DK11796555.8T DK2582721T3 (en) 2010-06-17 2011-06-17 USEFUL ANTIBODIES FOR PASSIVE INFLUENZA IMMUNIZATION

Country Status (12)

Country Link
US (1) US10676520B2 (OSRAM)
EP (1) EP2582721B1 (OSRAM)
JP (1) JP6050747B2 (OSRAM)
KR (1) KR101849738B1 (OSRAM)
CN (2) CN106397584A (OSRAM)
AU (2) AU2011268072C1 (OSRAM)
BR (1) BR112012032185A2 (OSRAM)
CA (1) CA2839421C (OSRAM)
DK (1) DK2582721T3 (OSRAM)
ES (1) ES2687706T3 (OSRAM)
RU (1) RU2635999C2 (OSRAM)
WO (1) WO2011160083A1 (OSRAM)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013086052A2 (en) 2011-12-05 2013-06-13 Trellis Bioscience, Llc Antibodies useful in passive influenza immunization
US9969794B2 (en) 2012-05-10 2018-05-15 Visterra, Inc. HA binding agents
MA38176A1 (fr) 2012-11-13 2017-06-30 Genentech Inc Nouvel anticorps anti-hemagglutinine, utile pour le traitement, l'inhibition ou la prévention de l’infection virale a grippe a
WO2014152841A1 (en) 2013-03-14 2014-09-25 Contrafect Corporation Composition and methods based on neutralizing antibodies delivered intranasally for enhanced therapeutic efficacy
US10639370B2 (en) 2014-02-04 2020-05-05 Contrafect Corporation Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof
RU2720282C1 (ru) * 2014-02-04 2020-04-28 Контрафект Корпорейшн Антитела, подходящие для пассивной иммунизации против гриппа, и их композиции, комбинации и способы применения
CN106132982A (zh) * 2014-03-20 2016-11-16 因弗拉克斯有限责任公司 用于治疗病毒性肺炎的C5a抑制剂
TWI702229B (zh) 2014-12-19 2020-08-21 美商再生元醫藥公司 流行性感冒病毒血球凝集素之人類抗體
US10513553B2 (en) 2015-11-13 2019-12-24 Visterra, Inc. Compositions and methods for treating and preventing influenza
CA3015347A1 (en) 2016-02-24 2017-08-31 Visterra, Inc. Formulations of antibody molecules to influenza virus
CN109476728A (zh) * 2016-07-14 2019-03-15 生命北极公司 脑部递送蛋白
EP3731862A1 (en) * 2017-12-29 2020-11-04 Development Center for Biotechnology A universal vaccine against influenza
CA3088194A1 (en) 2018-01-26 2019-08-01 Regeneron Pharmaceuticals, Inc. Human antibodies to influenza hemagglutinin
JP2022521819A (ja) 2019-03-25 2022-04-12 ビステラ, インコーポレイテッド インフルエンザを処置および予防するための組成物および方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6235708B1 (en) 1998-11-20 2001-05-22 Zymogenetics, Inc Testis-specific cystatin-like protein cystatin T
US20020006656A1 (en) 1999-12-23 2002-01-17 Holloway James L. Zcys5: a member of the cystatin superfamily
KR100708398B1 (ko) 2002-03-22 2007-04-18 (주) 에이프로젠 인간화 항체 및 이의 제조방법
AU2004220549B2 (en) 2003-03-07 2007-07-05 Instituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Influenza virus vaccine
SG128680A1 (en) * 2003-07-22 2007-01-30 Crucell Holland Bv Binding molecules against sars-coronavirus and uses thereof
RU2366662C2 (ru) * 2003-07-23 2009-09-10 Фуджирибайо Инк. Моноклональное антитело к вирусу типа а гриппа и устройство для иммунного анализа с использованием антитела
US7413868B2 (en) 2003-11-05 2008-08-19 Trellis Bioscience, Inc. Use of particulate labels in bioanalyte detection methods
JP2009537147A (ja) 2006-05-15 2009-10-29 シー レーン バイオテクノロジーズ, エルエルシー インフルエンザウイルスに対する中和抗体
EP2059532B1 (en) 2006-09-07 2012-12-26 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof
NO347649B1 (no) * 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
US20110038935A1 (en) * 2007-12-06 2011-02-17 Marasco Wayne A Antibodies against influenza virus and methods of use thereof
US20100040635A1 (en) * 2008-03-28 2010-02-18 Sea Lane Biotechnologies Neutralizing antibodies to influenza viruses
BRPI0911699B8 (pt) 2008-07-25 2023-02-28 Inst Res Biomedicine vetor, célula, composição farmacêutica, uso de um anticorpo, ou fragmento de ligação a antígeno deste
TW201019959A (en) * 2008-08-19 2010-06-01 Regeneron Pharma Human antibodies to human RANKL
WO2010074656A1 (en) * 2008-12-24 2010-07-01 Temasek Life Sciences Laboratory Limited Monoclonal antibodies specific to the fusion peptide from hemagglutinin from influenza a viruses and uses thereof
WO2011117848A1 (en) 2010-03-26 2011-09-29 Pomona Ricerca S.R.L. Full-length immunoglobulins of the igg isotvpe capable of recognizing a heterosubtvpe neutralizing epitope on the hemagglutinin stem region and their use as anti-influenza medicament
EP2603237A4 (en) * 2010-08-12 2014-05-21 Theraclone Sciences Inc ANTI-HEMAGGLUTININE ANTIBODY COMPOSITIONS AND METHOD FOR THEIR USE
US20130289246A1 (en) * 2010-09-30 2013-10-31 Vanderbilt University Influenza virus antibodies and immunogens and uses therefor

Also Published As

Publication number Publication date
EP2582721A1 (en) 2013-04-24
KR20130137584A (ko) 2013-12-17
KR101849738B1 (ko) 2018-04-17
ES2687706T3 (es) 2018-10-26
EP2582721A4 (en) 2013-11-20
BR112012032185A2 (pt) 2016-10-11
WO2011160083A1 (en) 2011-12-22
CN106397584A (zh) 2017-02-15
RU2013102073A (ru) 2014-07-27
AU2011268072C1 (en) 2017-10-19
CN103209994B (zh) 2016-10-12
JP6050747B2 (ja) 2016-12-21
US20120020971A1 (en) 2012-01-26
RU2635999C2 (ru) 2017-11-17
CN103209994A (zh) 2013-07-17
US10676520B2 (en) 2020-06-09
AU2017203924A1 (en) 2017-07-06
AU2011268072B2 (en) 2017-03-09
EP2582721B1 (en) 2018-08-22
CA2839421A1 (en) 2011-12-22
JP2013531993A (ja) 2013-08-15
CA2839421C (en) 2019-12-03
AU2011268072A1 (en) 2013-01-31
AU2017203924B2 (en) 2019-08-08
AU2011268072A2 (en) 2013-02-28

Similar Documents

Publication Publication Date Title
DK2582721T3 (en) USEFUL ANTIBODIES FOR PASSIVE INFLUENZA IMMUNIZATION
AU2012347878B2 (en) Antibodies useful in passive influenza immunization
KR102535195B1 (ko) 항-코로나바이러스 항체 및 사용 방법
AU2020203853C1 (en) Human immunodeficiency virus (HIV)-neutralizing antibodies
AU2021227687B2 (en) Antibodies against SARS-CoV-2 and methods of using the same
KR102602417B1 (ko) G-단백질 커플화 수용체를 표적화하는 항체 및 이의 사용 방법
CN108640989B (zh) 可结合并中和b型流感病毒的人类结合分子及其用途
EP3689909A1 (en) Tigit antibody, antigen-binding fragment thereof, and medical use thereof
KR20230002261A (ko) 항-sars-cov-2 중화 항체 및 이의 사용 방법
CN115768790A (zh) 针对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的人单克隆抗体
KR20220038415A (ko) 엔테로바이러스 d68에 대한 인간 모노클로날 항체
TW200925279A (en) Methods for recombinant manufacturing of anti-RSV antibodies
CN101679513A (zh) 用于治疗呼吸道合胞病毒感染的重组抗体
CN116194476A (zh) 针对sars-cov-2的抗体和其使用方法
KR20140012098A (ko) 인플루엔자의 치료 및 진단을 위한 조성물 및 방법
KR101900435B1 (ko) 인간 사이토메갈로바이러스 gB 단백질에 대한 고친화도 인간 항체
TW202300526A (zh) 針對gdf-15的抗體
AU2025201226A1 (en) Monoclonal antibodies and cocktails for treatment of Ebola infections
KR102880907B1 (ko) 한타바이러스에 대한 인간 모노클로날 항체 및 이의 사용 방법
KR20230042598A (ko) SARS-CoV-2 중화 항체 또는 그 단편
CN114685653B (zh) 抗新冠病毒受体结合区域表位中和抗体及其应用
CN102238963A (zh) 完全人源性流感m2特异性抗体
KR20210046725A (ko) 신규 암 면역요법 항체 조성물
KR102467943B1 (ko) 항-rsv 항체 및 이를 포함하는 약학적 조성물
RU2782256C2 (ru) Антитела к коронавирусу и способы применения